AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Pediatric Vitiligo: Considerations and Treatments

Description

Anchika Kashik, a pediatrician and dermatologist, discusses pediatric vitiligo, emphasizing unique considerations for children affected by this condition. She notes that childhood vitiligo often presents a more severe course, necessitating regular monitoring even if the initial affected area is small. Females are more commonly affected, particularly after age three. Vitiligo can be linked to comorbid conditions such as Halo nevi, which may later evolve into vitiligo, as well as other disorders like allergies and autoimmune issues. The psychosocial impact is significant; children may suffer from bullying and emotional distress due to visible changes caused by the condition, affecting their quality of life and social interactions. Standard treatments include topical steroids and phototherapy, though the latter can be logistically challenging for families. New treatments like JAK inhibitors show promise, with preliminary studies indicating adolescents may respond well, sometimes even better than adults. Options for managing segmental vitiligo, which is notoriously difficult to treat, are also discussed, including a noteworthy case report of complete repigmentation using tofacitinib combined with phototherapy. Overall, the presentation highlights the necessity for tailored approaches to treatment and monitoring in pediatric patients with vitiligo.

View more

Conclusions

  • Childhood-onset vitiligo exhibits a more progressive and severe course compared to later onset.
  • There is a female predominance in pediatric vitiligo, although early-onset cases show higher male prevalence.
  • Segmental vitiligo is more common in children and can be particularly difficult to treat.
  • Pediatric vitiligo is associated with several comorbidities including Halo nevi, atopic conditions, and thyroid disorders.
  • Vitamin D deficiency and other systemic disorders such as autoimmune diseases have been observed in pediatric vitiligo patients.
  • Visual acuity deficits in pediatric patients with vitiligo are not significantly different when controlled for family history of visual loss.
  • Hearing loss incidence is comparable between vitiligo patients and healthy controls, which is reassuring for screening purposes.
  • Pediatric vitiligo significantly impacts quality of life and is correlated with depression, particularly affecting emotional development in preteens and teenagers.
  • Standard treatments for pediatric vitiligo include topical steroids and UV therapies, but compliance can be challenging with phototherapy.
  • Short outdoor UV exposure may enhance the effectiveness of topical treatments for children.
  • Recent studies show that topical JAK inhibitors like ruxolitinib can effectively treat pediatric vitiligo, with higher response rates in adolescents compared to adults.
  • Complete remission rates for adolescents using ruxolitinib cream are notably higher than those for adults, indicating a possible greater responsiveness in younger patients.
  • In a case series, the use of tofacitinib plus phototherapy led to complete repigmentation in some cases of segmental vitiligo, suggesting new avenues for treatment.
  • Farajzadeh, S., et al. (2023). "Global clinicoepidemiological pattern of childhood vitiligo: a systematic review and meta-analysis." BMJ Paediatr Open 7.
  • Meister, H. M., et al. (2024). "Case series of topical 1.5% ruxolitinib cream for pediatric vitiligo." JAAD Case Rep 54: 27-30.
  • Meiyun, L., et al. (2024). "Epidemiologic and clinical differences between early-onset and later-onset childhood vitiligo: A retrospective cohort study." Journal of the American Academy of Dermatology 91(1): 125-127.
  • Metko, D., et al. (2025). "Pediatric Vitiligo Treatment with JAK Inhibitors: A Scoping Review." Journal of Cutaneous Medicine and Surgery 29(1): 83-84.
  • Olamiju, B. and B. G. Craiglow (2020). "Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child." Pediatr Dermatol 37(4): 754-755.
  • Renert-Yuval, Y., et al. (2024). "Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients." JAMA Dermatol 160(4): 453-461.
  • Silverberg, J. I. and N. B. Silverberg (2014). "Quality of life impairment in children and adolescents with vitiligo." Pediatr Dermatol 31(3): 309-318.
  • Tissera, K. A., et al. "Investigation of Hearing Loss in Pediatric Vitiligo." Pediatric Dermatology n/a(n/a).
  • Tissera, K.A., Buros-Stein, A., Delva, C.A., Mayur, O., Hawryluk, E.B., Harris, J. and Garza-Mayers, A.C. (2025), No Association of Pediatric Vitiligo With Visual Acuity Deficits. Pediatric Dermatology.